Disease relevance of 2-[bis[2-(carboxymethyl-(methylcarbamoylmethyl)amino)ethyl]amino]acetic acid

• It was found that all had been exposed to gadodiamide before the development of nephrogenic systemic fibrosis [1].
• Renal insufficiency: usefulness of gadodiamide-enhanced renal angiography to supplement CO2-enhanced renal angiography for diagnosis and percutaneous treatment [2].
• A bolus of 0.05 mmol per kilogram of body weight gadopentetate dimeglumine or gadodiamide was administered [3].
• Gadodiamide administration causes spurious hypocalcemia [4].
• CONCLUSION: Gadodiamide-enhanced MR angiography performed with single and triple doses is safe and effective for assessing major abdominal arterial stenoses [5].

High impact information on 2-[bis[2-(carboxymethyl-(methylcarbamoylmethyl)amino)ethyl]amino]acetic acid

• Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging [1].
• MATERIALS AND METHODS: LLC-PK1 cells were incubated with iomeprol, gadopentetate dimeglumine, gadobenate dimeglumine, gadoterate meglumine, gadodiamide, and corresponding mannitol solutions for 24 hours at 37 degrees C in two experimental settings: measurements with equally attenuating solutions and measurements with equimolar solutions [6].
• CONCLUSION: Noninferiority of gadodiamide versus gadopentetate was verified based on the primary end point, which was accuracy for detection of the main stenosis with enhanced 3D MR angiography compared with DSA [7].
• T1 values increased significantly (P < .05) to 720 msec +/- 7 for 0.05 mmol/mL gadodiamide and 445 msec +/- 6 for 0.10 mmol/mL gadodiamide 30 minutes after injection but remained significantly lower than those of remote myocardium (879 msec +/- 8) [8].
• CONCLUSION: Gadoversetamide and gadodiamide caused a transient artifact in measurement of serum calcium levels with an OCP assay but not with an arzenazo III technique or inductively coupled plasma mass spectrometry [9].

Chemical compound and disease context of 2-[bis[2-(carboxymethyl-(methylcarbamoylmethyl)amino)ethyl]amino]acetic acid

• PURPOSE: To prospectively evaluate accuracy of gadolinium-enhanced three-dimensional (3D) magnetic resonance (MR) angiography with gadodiamide and gadopentetate dimeglumine (0.1 mmol/kg), with intraarterial DSA as reference standard, for imaging abdominal and iliac arterial stenoses [7].
• PURPOSE: To estimate and compare the fractional distribution volume (fDV) of gadodiamide injection and technetium 99m-diethylenetriaminepentaacetic acid (DTPA) in the reperfused myocardium of rat hearts subjected to various durations of ischemia [10].
• METHODS: Between 1999 and 2002, gadodiamide-based arteriography was used in 20 patients (12 men; mean age 69 years) with significant baseline renal insufficiency (creatinine > or =1.7 mg/dL) undergoing renal artery stenting for > or =70% stenoses in 25 renal arteries [11].
• In regard to the control experiments, for all three variables (necrosis, edema, and inflammation), there was no statistically significant difference between the results with gadoteridol or gadodiamide and those with saline [12].
• Lower extremity arteriography with use of iodinated contrast material or gadodiamide to supplement CO2 angiography in patients with renal insufficiency [13].

Biological context of 2-[bis[2-(carboxymethyl-(methylcarbamoylmethyl)amino)ethyl]amino]acetic acid

• A high concentration of gadodiamide (0.5 mol/L) was used to demarcate the borders of the area of interest, or "hit the target." Blood pressure, heart rate, and oxygen saturation were measured before and after the intervention [14].
• In this report, we apply contrast-enhanced magnetic resonance imaging to study the pharmacokinetics and extent of non-ionic gadodiamide transport into brain tissue in vivo after intracerebroventricular administration [15].
• Cell volume fraction was calculated as 1 - f(ECS), where f(ECS) is the distribution volume of gadodiamide in the slice [16].
• Effects of three different doses of a bolus injection of gadodiamide: assessment of regional cerebral blood volume maps in a blinded reader study [17].
• Cell proliferation decreased following exposure to gadodiamide in a dose-dependent manner [18].

Anatomical context of 2-[bis[2-(carboxymethyl-(methylcarbamoylmethyl)amino)ethyl]amino]acetic acid

• It is concluded that gadodiamide injection is safe and effective for MR imaging of the head and spine in patients with suspected abnormalities of the central nervous system [19].
• Gadodiamide-enhanced angiograms appeared to be better than CO2-enhanced angiograms for help in identifying renal artery occlusions, visualizing renal vessels incompletely filled with CO2, and determining the progress of intervention [2].
• Echo-planar MR imaging of normal and ischemic myocardium with gadodiamide injection [20].
• Skull base tumors: gadodiamide injection--enhanced MR imaging--drop-out effect in the early enhancement pattern of paragangliomas versus different tumors [21].
• Rapid echo-planar (EP) magnetic resonance (MR) imaging was used to monitor the first pass of a bolus of gadodiamide injection in the hearts of normal rats and rats subjected to left coronary artery occlusion [20].

Associations of 2-[bis[2-(carboxymethyl-(methylcarbamoylmethyl)amino)ethyl]amino]acetic acid with other chemical compounds

• These reduced calcium measurements were correlated with serum creatinine level (r = 0.39, P <.001), gadodiamide dose (r = 0.37, P <.001), and time between gadodiamide injection and phlebotomy (r = -0.28, P <.001) [4].
• MATERIALS AND METHODS: In vitro attenuation measurements of multiple dilutions of gadodiamide and ioversol were compared [22].
• In vivo perfusions with the gadodiamide (GdDTPA-BMA) chelate-bound paramagnetic gadolinium ion resulted in dynamic temporal enhancement of the scala vestibule and scala tympani, but did not penetrate the scala media [23].
• After performing sagittal, coronal, and axial T1-weighted MR imaging of the brain, 0.02-0.04 mmol of gadodiamide was injected into the lateral ventricle [24].
• MATERIALS AND METHODS: Lower extremity angiographic procedures (diagnostic and diagnostic/intervention) were performed in 40 patients with CRI (baseline serum creatinine [Cr] > 1.5 mg/dL) using CO2 alone or CO2 supplemented with the use of either nonionic contrast material or gadodiamide (up to 0.4 mmol/kg) [13].

Gene context of 2-[bis[2-(carboxymethyl-(methylcarbamoylmethyl)amino)ethyl]amino]acetic acid

• PURPOSE: To evaluate the time-signal intensity (SI) curves generated from intravenous (IV) gadodiamide-enhanced dynamic magnetic resonance (MR) urographic scans for identifying vesicoureteral reflux (VUR) during bladder filling [25].
• Dynamic contrast-enhanced MR images of 12 patients with acute pneumonia and 13 patients with exacerbation of COPD were acquired in both the coronal and transaxial planes (an inversion recovery prepared gradient-echo sequence using 0.05 mmol/kg gadodiamide/injection) [26].
• Gadodiamide (Omniscan, Amersham Health, Cork, Ireland) and gadoversetamide (OptiMARK, Mallinckrodt, St. Louis, MO) did produce noticeable-and therefore potentially misleading-effects at these concentrations [27].
• METHODS: Nineteen patients with Crohn's disease (CD), 8 with ulcerative colitis (UC), and 5 healthy controls (HC) were examined using MRI (0.1 T) before and after intravenously administered gadodiamide and glucagon [28].
• For MR-angiography, a Flash 3D sequence was utilized following injection of 5 mL diluted gadodiamide (Omniscan; Amersham Buchler, Braunschweig, Germany) via the arterial access [29].

Analytical, diagnostic and therapeutic context of 2-[bis[2-(carboxymethyl-(methylcarbamoylmethyl)amino)ethyl]amino]acetic acid

• In normal brain, dose-dependent decreases in signal intensity were observed after intravenous injection of 0.15-0.50 mmol/kg dysprosium-diethylenetriaminepentaacetic acid bismethylamide or gadodiamide injection [30].
• Seventy-three patients (34 male, 39 female; age range, 17-84 years) who were clinically suspected of having RAS underwent contrast material-enhanced (gadodiamide) saturation-recovery turbo fast low-angle shot imaging for measurement of renal perfusion and high-spatial-resolution MR angiography for RAS detection and grading [31].
• Multicenter study of gadodiamide injection as a contrast agent in MR imaging of the brain and spine [19].
• Results of MR angiography with 0.1 mmol/kg and 0.3 mmol/kg doses of gadodiamide were compared with those of digital subtraction angiography (DSA) and according to dose [5].
• The fDVs of gadodiamide injection and (99m)Tc-DTPA were measured and compared by using inversion-recovery echo-planar imaging and autoradiographic phosphor imaging, respectively [10].

References